TY - JOUR
T1 - Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer
AU - Liu, Liqian
AU - Coker, Ann L.
AU - Du, Xianglin L.
AU - Cormier, Janice N.
AU - Ford, Charles E.
AU - Fang, Shenying
PY - 2008/6/1
Y1 - 2008/6/1
N2 - Background: This study aimed to address long-term survival in a large population-based cohort of men with prostate cancer receiving radical prostatectomy compared to other treatments. Methods: We studied 5,845 patients diagnosed with local/regional stage prostate cancer at age 65-74 in 1992 with comorbidity score <2, who were defined as potential candidates for radical prostatectomy and identified from the SEER (Surveillance, Epidemiology and End Results)-Medicare cohort with median follow-up of 11 years. Results: Of 5,845 patients, 10-year all-cause survival rates were the highest for patients receiving radical prostatectomy (81.0%; 95% CI: 79.4-82.4%), followed by radical prostatectomy in combination with radiotherapy (67.6%; 62.0-72.5%), radiotherapy (60.5%; 58.3-62.6%), and were the lowest for watchful-waiting (50.7%; 47.5-53.8%). A similar pattern was found for 10-year prostate cancer-specific survivals by treatments. After adjusting for age, ethnicity, region, Gleason Score, comorbidity, median annual household income, hormone therapy and chemotherapy, the hazard ratio of all-cause mortality was 0.31 (95% CI: 0.25-0.37) for radical prostatectomy and 0.38 (95% CI: 0.28-0.52) for radical prostatectomy plus radiation therapy compared to those with watchful-waiting. Conclusions: There was a significant long-term survival benefit in men receiving radical prostatectomy compared to those receiving watchful-waiting or radiotherapy.
AB - Background: This study aimed to address long-term survival in a large population-based cohort of men with prostate cancer receiving radical prostatectomy compared to other treatments. Methods: We studied 5,845 patients diagnosed with local/regional stage prostate cancer at age 65-74 in 1992 with comorbidity score <2, who were defined as potential candidates for radical prostatectomy and identified from the SEER (Surveillance, Epidemiology and End Results)-Medicare cohort with median follow-up of 11 years. Results: Of 5,845 patients, 10-year all-cause survival rates were the highest for patients receiving radical prostatectomy (81.0%; 95% CI: 79.4-82.4%), followed by radical prostatectomy in combination with radiotherapy (67.6%; 62.0-72.5%), radiotherapy (60.5%; 58.3-62.6%), and were the lowest for watchful-waiting (50.7%; 47.5-53.8%). A similar pattern was found for 10-year prostate cancer-specific survivals by treatments. After adjusting for age, ethnicity, region, Gleason Score, comorbidity, median annual household income, hormone therapy and chemotherapy, the hazard ratio of all-cause mortality was 0.31 (95% CI: 0.25-0.37) for radical prostatectomy and 0.38 (95% CI: 0.28-0.52) for radical prostatectomy plus radiation therapy compared to those with watchful-waiting. Conclusions: There was a significant long-term survival benefit in men receiving radical prostatectomy compared to those receiving watchful-waiting or radiotherapy.
KW - Older men
KW - Prostate cancer
KW - Radical prostatectomy
KW - Survival
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=44849097287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44849097287&partnerID=8YFLogxK
U2 - 10.1002/jso.21028
DO - 10.1002/jso.21028
M3 - Article
C2 - 18381603
AN - SCOPUS:44849097287
SN - 0022-4790
VL - 97
SP - 583
EP - 591
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 7
ER -